Protagonist Therapeutics has delivered strong Phase 3 data for both icotrokinra (psoriasis) and rusfertide (polycythemia vera), supporting blockbuster potential. Lucrative partnerships with Johnson & ...
Fintel reports that on December 6, 2024, BMO Capital initiated coverage of Protagonist Therapeutics (NasdaqGM:PTGX) with a Outperform recommendation. As of December 3, 2024, the average one-year price ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results